Clinical pharmacology of bimatoprost (Q36572646)

15 August 2017

1 reference

title

Clinical pharmacology of bimatoprost (English)

1 reference

15 August 2017

1 reference

Louis B Cantor

1

1 reference

PubMed ID

16922657

15 August 2017

language of work or name

English

0 references

publication date

1 June 2005

1 reference

Expert Opinion on Drug Metabolism & Toxicology

15 August 2017

1 reference

15 August 2017

1

1 reference

15 August 2017

1

1 reference

15 August 2017

151-157

1 reference

Number of people with glaucoma worldwide

15 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.1.151

Answers from the ocular hypertension treatment study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.1.151

Target pressure--glaucomatologists' holey grail.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.1.151

Diurnal intraocular pressure variations: an analysis of 690 diurnal curves

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.1.151

Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.1.151

Medical treatment of glaucoma--a reappraisal of the risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.1.151

Pharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.1.151

Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.1.151

Bimatoprost and its free acid are prostaglandin FP receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.1.151

Studies using isolated uterine and other preparations show bimatoprost and prostanoid FP agonists have different activity profiles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.1.151

Bimatoprost and prostaglandin F(2 alpha) selectively stimulate intracellular calcium signaling in different cat iris sphincter cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.1.151

Bimatoprost: a novel antiglaucoma agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.1.151

Prostaglandin ethanolamides (prostamides): in vitro pharmacology and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.1.151

Comparison of Prostaglandin F2α, Bimatoprost (Prostamide), and Butaprost (EP2 Agonist) on Cyr61 and Connective Tissue Growth Factor Gene Expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.1.151

Upregulation of orphan nuclear receptor Nur77 following PGF(2alpha), Bimatoprost, and Butaprost treatments. Essential role of a protein kinase C pathway involved in EP(2) receptor activated Nur77 gene transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.1.151

Additivity of bimatoprost or travoprost to latanoprost in glaucomatous monkey eyes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.1.151

Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.1.151

Ocular hypotensive efficacy of bimatoprost when used as a replacement for latanoprost in the treatment of glaucoma and ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.1.151

Efficacy of bimatoprost in glaucoma and ocular hypertension unresponsive to latanoprost

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.1.151

Detection of the free acid of bimatoprost in aqueous humor samples from human eyes treated with bimatoprost before cataract surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.1.151

A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.1.151

Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.1.151

One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.1.151

A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.1.151

A 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.1.151

Bimatoprost: a member of a new class of agents, the prostamides, for glaucoma management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.1.151

24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.1.151

Two-year double-masked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.1.151

A randomised, double masked, multicentre clinical trial comparing bimatoprost and timolol for the treatment of glaucoma and ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.1.151

Bimatoprost 0.03% versus travoprost 0.004% in black Americans with glaucoma or ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.1.151

Ocular hypotensive efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.1.151

A retrospective review of non-responders to latanoprost

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.1.151

21 January 2018

Identifiers

DOI

10.1517/17425255.1.1.151

1 reference

15 August 2017

1 reference

PubMed ID

16922657